Intense Pulsed Light Study for Dry Eye Disease

Not Applicable

Completed

Interventions: Procedure: Sham Treatment
Device: Intense Pulsed Light Therapy

Brief Summary: This study will evaluate the efficacy of intense pulsed light (IPL) therapy for the treatment of dry eye disease. One eye of the participant will be randomized to receive the IPL treatment.

Detailed Description: Dry eye disease (DED) affects tears and the front surface of the eye. Patients who have DED can experience symptoms of discomfort, blurry vision, redness, and pain. DED can also cause tears to become unstable which could result in damage to the front surface of the eye.

There are two types of DED. The one the investigators are studying is called evaporative dry eye disease. This type of DED occurs because the pores on the eyelids are not functioning properly. In preliminary studies, a new treatment called Intense Pulsed Light (IPL) has shown promise to reduce signs and symptoms of evaporative DED. IPL is a non-invasive and non-laser light treatment that was approved in 1995 by the FDA for dermatology. It is commonly used for treatment of facial rosacea, acne, and hair, wrinkle and lesion removal. It is not currently approved for the treatment of dry eye disease. This treatment is thought to provide relief of evaporative DED symptoms and improve the expression of the pores on the edge of the eyelid.

Recruitment & Eligibility

Inclusion Criteria

Willing and able to provide informed consent;
Diagnosed with evaporative dry eye disease with symptoms for 6 months or more;
Able and willing to comply with follow-up visits, phone calls and intense pulsed light treatments;
Agree to using an effective method of birth control during the course of the study;
Agree to continue current dry eye treatments during the course of the study;
Fitzpatrick skin scale of 1 (very fair) to 4 (olive) as determined by an investigator.

Exclusion Criteria

Darker skinned individuals defined by the Fitzpatrick scale 5 and 6 as determined by an investigator;
Neurotrophic keratitis;
Ectropion, trauma, or any other lid abnormalities;
Previous diagnosis of Stevens Johnson syndrome or graft versus host disease;
Ocular burn, active ocular infection, or active ocular inflammation;
Currently pregnant or trying to become pregnant in the next 5 months;
Systemic conditions or currently taking medications which makes light therapy contraindicated (the use of doxycycline is allowed);
Tattoos in the treatment area;
Patients who have had intense pulsed light therapy, Lipiflow or Meibothermoflo within the past six months;
Contact lens wear more than one time/week or history of refractive surgery;
Glaucoma drop use
Ophthalmic steroid use within the past 30 days;
Punctal plugs if instilled within 30 days of the start of the study;
Obvious asymmetry between the two eyes deemed significant by the investigators (such as punctal plugs or cautery in only one eye, etc);
History of a trabeculectomy or tube surgery;
Uncontrolled ocular or systemic disease;
Ocular or eyelid surgery within the last 6 months;
Any condition which leads the investigator to believe that the patient cannot comply with the study requirements and/or the patient may be placed at risk with participation.

Arm && Interventions

Group	Intervention	Description
Sham Treatment	Sham Treatment	Participants will have the other eye randomized to receive a sham treatment. The sham treatment will be conducted by placing the intense pulsed light (IPL) device to approximately 15 areas around the eye, lower eyelid, cheek, side of nose and temple without delivery of the light. The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
Intense Pulsed Light Treatment	Intense Pulsed Light Therapy	Participants will have one eye randomized to receive the intense pulsed light (IPL) therapy treatment while their other eye will receive the sham treatment. Participants will receive approximately 15 light spots to areas around the eye, lower eyelid, cheek, side of the nose and temple. The energy level will be based on skin type. IPL will be administered 4 times throughout the study.

Primary Outcome Measures

Name	Time	Method
Tear Breakup Time Average	16.5 weeks	Three tear breakup time measurements will be taken of each eye. The averages of those eyes treated with intense pulsed light treatment will be compared to those eyes that received the sham treatment.
Change in Scores of the Ocular Surface Disease Index Questionnaire	7 Months	Patients completed the Ocular Surface Disease Index Questionnaire at each visit before they received the IPL and sham treatments. The questionnaire is assessed on a scale of 0 to 100 with 0 meaning normal and the higher scores representing greater dry eye disease severity. This questionnaire has been validated to assess ocular symptoms for a patient but cannot be separated by eye. Therefore, the results cannot be given by treatment vs. sham, but for the participant overall.

Secondary Outcome Measures

Name	Time	Method

Locations (1): University of Michigan Kellogg Eye Center
🇺🇸
Ann Arbor, Michigan, United States